WO1989005822A1 - Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2) - Google Patents

Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2) Download PDF

Info

Publication number
WO1989005822A1
WO1989005822A1 PCT/AU1988/000485 AU8800485W WO8905822A1 WO 1989005822 A1 WO1989005822 A1 WO 1989005822A1 AU 8800485 W AU8800485 W AU 8800485W WO 8905822 A1 WO8905822 A1 WO 8905822A1
Authority
WO
WIPO (PCT)
Prior art keywords
igf
gly
cys
leu
peptide analogue
Prior art date
Application number
PCT/AU1988/000485
Other languages
French (fr)
Inventor
Francis John Ballard
John Campbell Wallace
Original Assignee
Gropep Pty. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gropep Pty. Ltd. filed Critical Gropep Pty. Ltd.
Priority to EP89900786A priority Critical patent/EP0346429B1/en
Priority to DE3852636T priority patent/DE3852636T2/en
Publication of WO1989005822A1 publication Critical patent/WO1989005822A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Definitions

  • This invention relates to growth factors, related compounds and their use.
  • Insulin-like growth factor-1 a somatomedin
  • Human IGF-1 hIGF-1
  • the serum mediator of growth hormone action somatomedin C
  • the amino acid sequence established for hIGF-1 beginning with the N-terminal glycine is:
  • ovine and chicken IGF-1 • differ from human IGF-1 only as follows: ovine IGF-1 : ala
  • Chicken IGF-1 ser 26 ; lys 41 , gin 50 , ile 64
  • IGF-1 may suppress the loss of body protein in severe human catabolic states such as following burns, infection or other trauma; (4) may improve wound healing in human subjects as well as in animals. IGF-1 can also be used to (5) support the growth of cells in culture.
  • IGF-2 Insulin-like growth factor-2
  • IGF-1 Insulin-like growth factor-2
  • hIGF-2 human IGF-2
  • N-terminal alanine The amino acid sequence established for human IGF-2 (hIGF-2) beginning with the N-terminal alanine is shown below. Upper case letters have been used to indicate the amino acids equivalent to the N-terminal 5 amino acids of hIGF-1:
  • bovine, ovine, porcine and chicken IGF-2 differ from human IGF-2 only as follows: bovine IGF-2 ser .32 ile 35 asn 36
  • ovine IGF-2 ser 32 i.,le35; asn36; a-l,a62
  • the compound destripeptide bIGF-1 but lacking the amino acid residues gly, pro and glu from the N-terminal, is effective in inhibiting protein breakdown and stimulating both protein synthesis and DNA synthesis in cellular systems at concentrations between 4 and 50 fold lower than required for entire bIGF-1.
  • IGF-1 peptides having N-terminal amino acid sequences in common with that of human/bovine/porcine IGF-1 the elimination of between 1 and 5 amino acid residues from the N-terminal also results in enchanced biological potencies.
  • the said N-terminal amino acid sequence is also a feature of the IGF-1 of rat, ovine, and chicken species.
  • IGF-1 insulin-like growth factor-1
  • IGF-2 factor-2
  • the N-terminal Ala-residue is absent so that the glutamic acid residue is at position 5 from the N-terminal.
  • the peptide analogue is a human, bovine, ovine, porcine or chicken insulin-like growth factor analogue. More preferably the peptide analogue is a human, bovine or porcine insulin-like growth factor-1 analogue.
  • the peptide analogue according to the present invention may be in a biologically pure form.
  • the peptide analogue is an insulin like growth factor-1 analogue in addition at least one of the Gly-, Pro-, or Thr- residues may be absent from the N-terminal in addition to the absence of the glutamic acid residue.
  • the glutamic acid residue may be replaced by a different amino acid residue.
  • Suitable amino acid residues to replace glutamic acid include glycine, glutamine, leucine, arginine, or lysine.
  • the replacement residue for glutamic acid will be a positively charged amino acid residue such as arginine or lysine.
  • glutamic acid residue may be replaced by glycine and the threonine residue normally adjacent to the glutamic acid may be replaced by a different amino acid residue, preferably arginine or glycine, most preferably arginine.
  • the N-terminal sequence is selected from Val-Leu-Cys-
  • the peptide analogue is an insulin-like growth factor-2 analogue.
  • at least one of the Ala-, Tyr-, Arg-, Pro-, Ser- or Thr- residues is absent from the N-terminal in addition to the absence of the glutamic acid residue.
  • glutamic acid residue is replaced by a different amino acid residue.
  • Suitable amino acid residues to replace glutamic acid include glycine, glutamine, leucine, arginine, or lysine.
  • Suitable amino acid residues to replace the threonine residue include arginine or glycine.
  • the replacement residue for glutamic acid will be a positively charged amino acid residue such as arginine or lysine.
  • glutamic acid residue may be replaced by glycine and the threonine residue normally adjacent to the glutamic acid may be replaced by a different amino acid residue, preferably arginine or glycine, most preferably arginine.
  • N-terminal sequence is selected from
  • the peptides lacking the glutamic acid residue bind poorly to the binding proteins produced by many cell types. This binding may be further reduced by the substitution of an arginine or lysine residue for the glutamic acid residue and optionally the substitution of the adjacent threonine residue by arginine or a lysine residue. Should a binding protein be present those other IGF-1 peptides that do bind have reduced potencies.
  • this invention provides peptide analogues that are suitable for cleavage of an engineered upstream asparagine.
  • the peptide analogues have higher potencies than IGF-1 in cultured cells.
  • the peptide analogues according to the present invention may form suitable replacements for IGF-1 and -2 in the following applications: (1) in humans to treat growth hormone deficiencies; (2) in farm animals to increase growth rates, increase the relative proportion of muscle or improve food conversion efficiency; (3) in humans to suppress the loss of body protein in severe catabolic states such as following burns, infection or other trauma; (4) in humans and animals to improve wound healing, and (5) to support the growth of cells in culture:
  • the present invention provides a pharmaceutical or veterinary composition that includes:
  • the peptide analogue may be present in amounts sufficient to provide a dose rate of approximately 0.01 to 10, preferably 0.1 to 1 milligrams/kg body weight/day.
  • the peptide analogue may be present in amounts of from approximately 0.02 to 2000 milligrams.
  • the peptide analogue may be present in concentrations from approximately 0.1 to 100 milligrams per litre.
  • a method for the treatment of protein accumulation deficiencies or protein loss in human subjects which method includes administering to a patient to be treated an effective amount of a peptide analogue of insulin-like growth factor-1 (IGF-1) or factor-2 (IGF-2) wherein at least the glutamic acid residue is absent at position 3 from the N-terminal of IGF-1 or at position 6 from the N-terminal of IGF-2 respectively.
  • IGF-1 insulin-like growth factor-1
  • IGF-2 factor-2
  • the peptide analogues may be administered to human subjects as a treatment for disorders associated with tissue wasting including, but not limited to, burns, skeletal trauma, infection, cancer, cystic fibrosis, Duchenne muscular dystrophy, Becker dystrophy, autosomal recessive dystrophy, polymyositis as well as other myopathies and acquired immune deficiency syndrome (AIDS) .
  • the peptide analogues may be administered parenterally or by injection.
  • a method for the treatment of wounds in animals including humans which method includes administering to a patient to be treated an effective amount of a peptide analogue of mammalian insulin-like growth factor-1 (IGF-1) or factor-2 (IGF-2) wherein at least the glutamic acid residue is absent at position 3 from the N-terminal of IGF-1 or at position 6 from the N-terminal of IGF-2 respectively.
  • IGF-1 insulin-like growth factor-1
  • IGF-2 factor-2
  • the peptide analogue may be applied externally to the wound or it may be administered by injection.
  • a method for the improvement of growth performance in animals which method includes administering to an animal to be treated an effective amount of a peptide analogue of insulin-like growth factor-1 (IGF-1) or factor-2 (IGF-2) wherein at least the glutamic acid residue is absent at position 3 from the N-terminal of IGF-1 or at position 6 from the N-terminal of IGF-2 respectively.
  • IGF-1 insulin-like growth factor-1
  • IGF-2 factor-2
  • An implant preferably a slow release pellet, is the preferred method of administration to farm animals as applied in conventional practice. Otherwise the peptide analogue may be administered by injection.
  • the peptide analogues of the present invention may be administered to premature or other human infants to promote growth, improve nitrogen status and to treat catabolic disorders.
  • the peptides may be administered as outlined above for tissue wasting conditions.
  • a method for the stimulation of cells in culture which method includes providing a culture medium, and an effective amount of a peptide analogue as described above; and adding the peptide analogue to the culture medium.
  • any standard culture medium may be used in accordance with this aspect of the present invention.
  • the culture medium may include Eagle's Minimal Essential Medium.
  • a method for the preparation of a peptide analogue of IGF-1 wherein at least the glutamic acid residue is absent at position 3 from the N-terminal which method includes providing a source of amino acids, and coupling the amino acids in sequence to form a peptide analogue having an N-terminal sequence selected from,
  • the peptide analogues may be produced by appropriate modifications to methods existing for the production of the full IGF-1 peptide. these modifications would be familiar to those familiar with the art.
  • the peptides related to human/bovine/ porcine IGF-1 may be synthesisted chemically using procedures developed for human IGF-1 (for example: Li et al., Proc. Natl. Acad. Sci, USA 80: 2216-2220, 1983) but with the final cycles of amino acid ligation modified.
  • Synthetic ovine or chicken IGF-1 as well as related IGF-1 and IGF-2 peptides may be produced by techniques similar to those used for human IGF-1 using amino acid sequence information for these peptides.
  • the peptides may also be produced following transformation of susceptible bacterial, yeast or tissue culture cell hosts with recombinant plasmids that include DNA sequences capable of directing the expression of the peptides.
  • the DNA sequence may be synthetic, chromosomal, cDNA or combination thereof.
  • the inserted coding sequences may incorporate deletion or omissions to account for differences between the sequence of peptide analogues and the full IGF-1 peptide.
  • the starting material was Boc-ala-phenylacetamido methyl resin. Coupling was effected in an Applied Biosystems Inc model 430A peptide synthesiser with preformed symmetric anhydrides of the Boc-aminoacids in dichloro- methane except for the derivatives of arginine, asparagine and glutamine which were coupled in dimethyl formamide (DMF) . In all cases a second coupling was performed in DMF. Samples of resin were removed after each cycle of synthesis and subjected to guantitive ninhydrin analysis (Sarin, V.K., Kent, S.B.H., Tarn, J.P., Merifield, R.B.; Anal. Biochem. 17, 147-157 (1981). Preview sequence analysis of the side-chain protected, resin-bound peptide was also carried out and together, these indicated an average repetitive yield of 99%.
  • Bioassays of purified synthetic peptides have been compared with pure humna/bovine/porcine IGF-1. The assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A peptide analogue of insulin-like growth factor-1 (IGF-1) or factor-2 (IGF-2) wherein at least the glutamic acid residue is absent at position 3 from the N-terminal of IGF-1 or at position 5 or 6 from the N-terminal of IGF-2.

Description

PEPTIDE ANALOGUES OF INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) OR FACTOR 2 (IGF-2)
This invention relates to growth factors, related compounds and their use.
Insulin-like growth factor-1, a somatomedin, is a small protein that has been shown to stimulate growth of a wide range of cells in culture. Human IGF-1 (hIGF-1) has been purified to homogeneity from human serum and its complete amino acid sequence established. The serum mediator of growth hormone action, somatomedin C, has been shown to have an identical sequence to hIGF-1 so that these two are now considered as being synonymous. The amino acid sequence established for hIGF-1 beginning with the N-terminal glycine is:
Gly-pro-glu-thr-leu-cys-gly-ala-glu-leu- val-asp-ala-leu-gin-phe-val-cys-gly-asp- arg-gly-phe-tyr-phe-asn-lys-pro-thr-gly- tyr-gly-ser-ser-ser-arg-arg-ala-pro-gin- thr-gly-ile-val-asp-glu-cys-cys-phe-arg- ser-cys-asp-leu-arg-arg-leu-glu-met-tyr- cys-ala-pro-leu-lys-pro-ala-lys-ser-ala- Bovine IGF-1 and porcine IGF-1 have identical sequences.
Using the conventional numbering system of the N-terminal glycine being residue #1 and the C-terminal alanine residue #70, ovine and chicken IGF-1 • differ from human IGF-1 only as follows: ovine IGF-1 : ala
Chicken IGF-1 : ser26; lys41, gin50, ile64
IGF-1 levels in serum correlate positively with growth rates in boys during adolescence and negatively with the degree of growth hormone deficiency in growth-retarded subjects, and to both growth rate and eventual size in mice transfected with growth hormone genes. These findings, indirectly linking IGF-1 concentrations with growth rates and supported by more direct evidence that administration of IGF-1 leads to restoration of growth rates in hypopituitary (growth hormone deficient) rats or mice and to increased growth rates in normal rats, have lead to the interpretation that IGF-1 might usefully be applied: (1) in humans to treat growth hormone deficiencies; (2) in farm animals to increase growth rates, increase the relative proportion of muscle and enhance food conversion efficiency. It is further suggested that administration of IGF-1: (3) may suppress the loss of body protein in severe human catabolic states such as following burns, infection or other trauma; (4) may improve wound healing in human subjects as well as in animals. IGF-1 can also be used to (5) support the growth of cells in culture.
The result of the above inferences is that there is a commercial demand for IGF-1 for use in animal trials, clinical investigations and for cell culture. However, only milligram amounts of hIGF-1, for example, are available by purification of tonnes of human serum protein and yields from recombinant DNA methods remain low.
Insulin-like growth factor-2 (IGF-2) like IGF-1, is a small protein that has been shown to stimulate growth of cells in culture. In most cases, these biological effects occur following interaction of IGF-2 with the same cellular receptor as is involved in IGF-1 actions. The amino acid sequence established for human IGF-2 (hIGF-2) beginning with the N-terminal alanine is shown below. Upper case letters have been used to indicate the amino acids equivalent to the N-terminal 5 amino acids of hIGF-1:
Ala-tyr-arg-PRO-SER-GLU-THR-LEU-cys-gly- gly-glu-leu-val-asp-thr-leu-gln-phe-val- cys-gly-asp-arg-gly-phe-tyr-phe-ser-arg- pro-ala-ser-arg-val-ser-arg-arg-ser-arg- gly-ile-val-glu-glu-cys-cys-phe-arg-ser- cys-asp-leu-ala-leu-leu-glu-thr-tyr-cys- ala-thr-pro-ala-lys-ser-glu
Using the conventional numbering system of the N-terminal alanine being residue #1 and the C-terminal glutamic acid being residue #67, bovine, ovine, porcine and chicken IGF-2 differ from human IGF-2 only as follows: bovine IGF-2 ser .32 ile 35 asn 36
ovine IGF-2 ser 32; i.,le35; asn36; a-l,a62
porcine IGF-2 asn .36
chicken IGF-2 ala 1 missing; gly3; thr4; al -a5; va,l32; g-ly33; asn35;
Figure imgf000005_0001
It has been disclosed (see PCT/AU87/00246 to applicants) that compounds corresponding to IGF-1 but lacking one to five, preferably three amino acid residues from the N-terminal of the molecule can exhibit a substantial increase in biological potency compared with the more complete compounds.
For example, the compound destripeptide bIGF-1 but lacking the amino acid residues gly, pro and glu from the N-terminal, is effective in inhibiting protein breakdown and stimulating both protein synthesis and DNA synthesis in cellular systems at concentrations between 4 and 50 fold lower than required for entire bIGF-1.
For IGF-1 peptides having N-terminal amino acid sequences in common with that of human/bovine/porcine IGF-1, the elimination of between 1 and 5 amino acid residues from the N-terminal also results in enchanced biological potencies. The said N-terminal amino acid sequence is also a feature of the IGF-1 of rat, ovine, and chicken species.
However, a useful property of the full IGF-1 peptide but not shared by the IGF-1 peptides having 1 to 5 N-terminal amino acids eliminated is that production by recombinant DNA methods that are part of the prior art are facilitated by the existence of N-terminal glycine. This facilitation occurs because an asparagine residue can be engineered upstream from the glycine and the asparagine/glycine bond cleaved selectively by mild hydroxylamine treatment following expression of the engineered gene.
Accordingly it is an object of the present invention to overcome, or at least alleviate, one or more of the difficulties related to the prior art.
Accordingly in a first aspect of the present invention there is provided a peptide analogue of insulin-like growth factor-1 (IGF-1) or factor-2 (IGF-2) wherein at least the glutamic acid residue is absent at position 3 from the N-terminal of IGF-1 or at position 5 or 6 from the N-terminal of IGF-2. It will be understood that in respect of chicken IGF-2 the N-terminal Ala-residue is absent so that the glutamic acid residue is at position 5 from the N-terminal.
Preferably the peptide analogue is a human, bovine, ovine, porcine or chicken insulin-like growth factor analogue. More preferably the peptide analogue is a human, bovine or porcine insulin-like growth factor-1 analogue.
The peptide analogue according to the present invention may be in a biologically pure form.
In a preferred aspect of the present invention, wherein the peptide analogue, is an insulin like growth factor-1 analogue in addition at least one of the Gly-, Pro-, or Thr- residues may be absent from the N-terminal in addition to the absence of the glutamic acid residue.
In a preferred aspect of the present invention the glutamic acid residue may be replaced by a different amino acid residue.
Suitable amino acid residues to replace glutamic acid include glycine, glutamine, leucine, arginine, or lysine.
More preferably the replacement residue for glutamic acid will be a positively charged amino acid residue such as arginine or lysine. Alternatively the glutamic acid residue may be replaced by glycine and the threonine residue normally adjacent to the glutamic acid may be replaced by a different amino acid residue, preferably arginine or glycine, most preferably arginine. Preferably the N-terminal sequence is selected from Val-Leu-Cys-
Arg-Leu-Cys-
Gly-Leu-Cys-
Gly-Thr-Leu-Cys-
Gly-Pro-Arg-Thr-Leu-Cys-
Gly-Pro-Gly-Arg-Leu-Cys-
Gly-Pro-Gly-Gly-Leu-Cys-
Gly-Pro-Gly-Thr-Leu-Cys-
Gly-Pro-Gln-Thr-Leu-Cys-
Gly-Pro-Lys-Thr-Leu-Cys-
Gly-Pro-Leu-Thr-Leu-Cys- with the Cys residue shown being that normally at position 6 from the N-terminal.
In a further preferred aspect of the present invention the peptide analogue is an insulin-like growth factor-2 analogue. Preferably in the peptide analogue, at least one of the Ala-, Tyr-, Arg-, Pro-, Ser- or Thr- residues is absent from the N-terminal in addition to the absence of the glutamic acid residue.
More preferably the glutamic acid residue is replaced by a different amino acid residue.
Suitable amino acid residues to replace glutamic acid include glycine, glutamine, leucine, arginine, or lysine. Suitable amino acid residues to replace the threonine residue include arginine or glycine.
More preferably the replacement residue for glutamic acid will be a positively charged amino acid residue such as arginine or lysine. Alternatively the glutamic acid residue may be replaced by glycine and the threonine residue normally adjacent to the glutamic acid may be replaced by a different amino acid residue, preferably arginine or glycine, most preferably arginine.
Preferably the N-terminal sequence is selected from
Ala-Tyr-Arg-Pro-Ser-Lys-Thr-Leu-Cys-
Ala-Tyr-Arg-Pro-Ser-Arg-Thr-Leu-Cys-
Ala-Tyr-Arg-Pro-Ser-Gly-Arg-Leu-Cys-
Ala-Tyr-Arg-Pro-Ser-Gly-Thr-Leu-Cys- with the Cys residue shown being that normally at position 9 from the N-terminal.
The peptides lacking the glutamic acid residue bind poorly to the binding proteins produced by many cell types. This binding may be further reduced by the substitution of an arginine or lysine residue for the glutamic acid residue and optionally the substitution of the adjacent threonine residue by arginine or a lysine residue. Should a binding protein be present those other IGF-1 peptides that do bind have reduced potencies.
In a preferred aspect wherein the glutamic acid residue is either substituted by another amino acid or eliminated and the N-terminal residue is glycine, this invention provides peptide analogues that are suitable for cleavage of an engineered upstream asparagine. The peptide analogues have higher potencies than IGF-1 in cultured cells.
The peptide analogues according to the present invention may form suitable replacements for IGF-1 and -2 in the following applications: (1) in humans to treat growth hormone deficiencies; (2) in farm animals to increase growth rates, increase the relative proportion of muscle or improve food conversion efficiency; (3) in humans to suppress the loss of body protein in severe catabolic states such as following burns, infection or other trauma; (4) in humans and animals to improve wound healing, and (5) to support the growth of cells in culture:
More specifically, the present invention provides a pharmaceutical or veterinary composition that includes:
(a) an effective amount of a peptide analogue of insulin¬ like growth factor-1 (IGF-1) or factor-2 (IGF-2) wherein at least the glutamic acid residue is absent at position 3 from the N-terminal of IGF-1 or at position 6 from the N-terminal of IGF-2 respectively and
(b) a pharmaceutically or veterinarily acceptable diluent, carrier or excipient therefor.
The peptide analogue may be present in amounts sufficient to provide a dose rate of approximately 0.01 to 10, preferably 0.1 to 1 milligrams/kg body weight/day. The peptide analogue may be present in amounts of from approximately 0.02 to 2000 milligrams. For cell culture applications the peptide analogue may be present in concentrations from approximately 0.1 to 100 milligrams per litre.
In a further preferred aspect of the present invention there is provided a method for the treatment of protein accumulation deficiencies or protein loss in human subjects, which method includes administering to a patient to be treated an effective amount of a peptide analogue of insulin-like growth factor-1 (IGF-1) or factor-2 (IGF-2) wherein at least the glutamic acid residue is absent at position 3 from the N-terminal of IGF-1 or at position 6 from the N-terminal of IGF-2 respectively.
The peptide analogues may be administered to human subjects as a treatment for disorders associated with tissue wasting including, but not limited to, burns, skeletal trauma, infection, cancer, cystic fibrosis, Duchenne muscular dystrophy, Becker dystrophy, autosomal recessive dystrophy, polymyositis as well as other myopathies and acquired immune deficiency syndrome (AIDS) . The peptide analogues may be administered parenterally or by injection.
In an alternative aspect there is provided a method for the treatment of wounds in animals including humans, which method includes administering to a patient to be treated an effective amount of a peptide analogue of mammalian insulin-like growth factor-1 (IGF-1) or factor-2 (IGF-2) wherein at least the glutamic acid residue is absent at position 3 from the N-terminal of IGF-1 or at position 6 from the N-terminal of IGF-2 respectively.
For the treatment of wounds in human subjects or in animals the peptide analogue may be applied externally to the wound or it may be administered by injection.
In a still further aspect there is provided a method for the improvement of growth performance in animals which method includes administering to an animal to be treated an effective amount of a peptide analogue of insulin-like growth factor-1 (IGF-1) or factor-2 (IGF-2) wherein at least the glutamic acid residue is absent at position 3 from the N-terminal of IGF-1 or at position 6 from the N-terminal of IGF-2 respectively.
An implant, preferably a slow release pellet, is the preferred method of administration to farm animals as applied in conventional practice. Otherwise the peptide analogue may be administered by injection.
The peptide analogues of the present invention may be administered to premature or other human infants to promote growth, improve nitrogen status and to treat catabolic disorders. The peptides may be administered as outlined above for tissue wasting conditions.
Accordingly in a still further aspect of the present invention, there is provided a method for the stimulation of cells in culture which method includes providing a culture medium, and an effective amount of a peptide analogue as described above; and adding the peptide analogue to the culture medium.
Any standard culture medium may be used in accordance with this aspect of the present invention. For example the culture medium may include Eagle's Minimal Essential Medium.
In a further aspect of the present invention there is provided a method for the preparation of a peptide analogue of IGF-1 wherein at least the glutamic acid residue is absent at position 3 from the N-terminal which method includes providing a source of amino acids, and coupling the amino acids in sequence to form a peptide analogue having an N-terminal sequence selected from,
Val-Leu-Cys-
Arg-Leu-Cys-
Gly-Leu-Cys-
Gly-Thr-Leu-Cys-
Gly-Pro-Arg-Thr-Leu-Cys-
Gly-Pro-Gly-Arg-Leu-Cys-
Gly-Pro-Gly-Gly-Leu-Cys-
Gly-Pro-Gly-Thr-Leu-Cys-
Gly-Pro-Gln-Thr-Leu-Cys-
Gly-Pro-Lys-Thr-Leu-Cys-
Gly-Pro-Leu-Thr-Leu-Cys- with the Cys residue being that normally at position 6 from the N-terminal.
The peptide analogues may be produced by appropriate modifications to methods existing for the production of the full IGF-1 peptide. these modifications would be familiar to those familiar with the art.
Specifically, the peptides related to human/bovine/ porcine IGF-1 may be synthesisted chemically using procedures developed for human IGF-1 (for example: Li et al., Proc. Natl. Acad. Sci, USA 80: 2216-2220, 1983) but with the final cycles of amino acid ligation modified. Synthetic ovine or chicken IGF-1 as well as related IGF-1 and IGF-2 peptides may be produced by techniques similar to those used for human IGF-1 using amino acid sequence information for these peptides. In accordance with the present invention, the peptides may also be produced following transformation of susceptible bacterial, yeast or tissue culture cell hosts with recombinant plasmids that include DNA sequences capable of directing the expression of the peptides. The DNA sequence may be synthetic, chromosomal, cDNA or combination thereof. The inserted coding sequences may incorporate deletion or omissions to account for differences between the sequence of peptide analogues and the full IGF-1 peptide.
The present invention will now be more fully described with respect to production of certain IGF-1 peptides and information on their biological potencies. It should be understood however, that the following description is illustrative only and should not be taken in any way as a restriction on the generality of the description foregoing. Example 1 Synthesis of IGF-1 peptides
Chemical synthesis of human/bovine/porcine IGF-1 peptides with between 1 and 4 amino acids from the normal N-terminal modified has been effected by the following procedure.
The starting material was Boc-ala-phenylacetamido methyl resin. Coupling was effected in an Applied Biosystems Inc model 430A peptide synthesiser with preformed symmetric anhydrides of the Boc-aminoacids in dichloro- methane except for the derivatives of arginine, asparagine and glutamine which were coupled in dimethyl formamide (DMF) . In all cases a second coupling was performed in DMF. Samples of resin were removed after each cycle of synthesis and subjected to guantitive ninhydrin analysis (Sarin, V.K., Kent, S.B.H., Tarn, J.P., Merifield, R.B.; Anal. Biochem. 17, 147-157 (1981). Preview sequence analysis of the side-chain protected, resin-bound peptide was also carried out and together, these indicated an average repetitive yield of 99%.
Portions of resin containing side-chain protected peptides corresponding to the complete sequence of hIGF-1 but with 4 to 0 amino acids not coupled at the N-terminal were removed. Other portions with between 4 and 3 amino acids not coupled at the N-terminal had amino acid residues coupled as required for specific analogues. Peptides were cleaved and deprotected according to Applied Biosystems Inc procedures and recovered as ether precipitates.
Peptides were redissolved in 6M guanidine hydrochloride pH 8.5 with Tris containing 10 mM dithioerythritol and desalted by reverse phase HPLC and dried. Oxidation of the reduced peptide was effected by dissolving in 8M urea, 0.1M Tris (pH8.0 with HCl) containing 13mM oxidized gluthathione and incubated at 25 for 15 hours. The sample was purified by reverse phase HPLC using a gradient of acetonitrile in 0.1% trifluoroacetic acid to elute the peptides and separate the biologically active form of the peptide from those forms lacking . the correct disulphide bonds and hence lacking full biological activity. The samples were dried prior to resuspension.
Biological activity was confirmed by the ability of the peptide to stimulate protein synthesis in L6 myoblasts.
It will be appreciated that various modifications and/or alterations may be introduced into the constructions and arrangementsof parts previouslydescribed without departing from the spirit or ambit of the present invention. Biological Activities of IGF-1 Peptides
Bioassays of purified synthetic peptides have been compared with pure humna/bovine/porcine IGF-1. The assays
3 involve the incorporation of H-labelled leucine into the total cell protein of L6 myoblasts as described by Francis et al. (Biochem. J. 233:207-213, 1986). The relative potencies are shown in Table 1 where the concentrations are expressed as percentages of that required to give a half- response with human/bovine/porcine IGF-1 (12 ng/ml) :
TABLE 1
Relative biological potencies of IGF-1 peptides in L6 myoblasts
N-terminal sequence (the Cys Concentration (percent of residue is that normally at that required to give a position 6 from the N-terminal) half-response with hIGF-1)
Human/bovine/porcine IGF-1 (Gly-Pro-Glu-Thr-Leu-Cys-) 100 Thr-Leu-Cys- 15 Val-Leu-Cys- 13 Gly-Leu-Cys- 15 Arg-Leu-Cys- 4 Gly-Thr-Leu-Cys- 16 Gly-Pro-Gly-Thr-Leu-Cys- 12 Gly-Pro-Gln-Thr-Leu-Cys- 18 Gly-Pro-Lys-Thr-Leu-Cys- 11 Gly-Pro-Leu-Thr-Leu-Cys- 18 Gly-Pro-Arg-Thr-Leu-Cys- 5 Gly-Pro-Gly-Gly-Leu-Cys 14 Gly-Pro-Gly-Arg-Leu-Cys 4
The higher potencies produced by the deletion or modification of the glutamic acid residue normally at position 3 of IGF-1 are not associated with a markedly increased competition of the peptide for binding to receptors on the L6 myoblasts, provided that binding is carried out at 4°C otherwise using the method of Ballard et al (Biochem. J. 233; 223-230, 1986) with human/bovine/porcine IGF-1 as radioligand. This apparent discrepancy is caused by the myoblasts producing a binding protein in addition to the receptor. This binding protein selectively binds those IGF-1 peptides that have a glutamic acid residue at position 3 from the N-terminal, thus preventing the peptide binding to the cell receptor. This interpretation is established by the following results [determined by the method of Martin and Baxter, J. Biol, Chem. 261: 8754-8760, (1986)] with purified binding proteins (see Table 2) .
TABLE 2
Relative abilities of IGF-1 Peptides to complete for the binding of labelled human/bovine/porcine IGF-1 to purified binding protein
N-terminal sequence (the Cys Potency for binding to the residue is that normally at protein where hIGF-1 = 100% position 6 from the N-terminal)
Human/bovine IGF-1
(Gly-Pro-Glu-Thr-Leu-Cys-) 100
Thr-Leu-Cys- 0.2
Val-Leu-Cys- 0.1
Gly-Leu-Cys- 0.1
Arg-Leu-Cys < 0.1
Gly-Thr-Leu-Cys- 1.0
Gly-Pro-Gly-Thr-Leu-Cys- 0.5
Gly-Pro-Gln-Thr-Leu-Cys- 1.0
Gly-Pro-Lys-Thr-Leu-Cys- 0.1
Gly-Pro-Leu-Thr-Leu-Cys- 0.5
Gly-Pro-Arg-Thr-Leu-Cys- < 0.1
Gly-Pro-Gly-Gly-Leu-Cys- 0.1
Gly-Pro-Gly-Arg-Leu-Cys- 0.1
Accordingly, from the data presented in Tables 1 and 2 it can be seen that: removal of the three N-terminal amino acids (Gly,Pro,Glu) from hIGF-1 leads to enhanced biological activity and minimal binding to binding proteins produced by the cells;
- removal of the three N-terminal amino acids together with substitution of the fourth amino acid (threonine) with arginine gives even greater biological potency as well as even lower binding to the binding proteins;
- removal of the two N-terminal amino acids (Gly,Pro) together with the substitution of the third amino acid (glutamic acid) with glycine leads to an IGF analogue that is more active biologically than hIGF-1 and binds poorly but significantly to the binding proteins;
- substitution of the Glutamic acid residue normally at position 3 in hIGF-1 with glycine, glutamine, lysine, leucine or arginine leads to enhanced potency and poor binding to binding proteins, with the effects greatest with the lysine or arginine substitutions; substitution of the glutamic acid residue normally at position 3 in hIGF-1 with glycine together with substitutions of glycine, arginine or valine for threonine at position 4 also produce increases in potency and decreased binding to binding proteins. Finally, it is to be understood that various other modifications and/or alterations may be made without departing from the spirit of the present invention as outlined herein.

Claims

1. A peptide analogue of insulin-like growth factor-1 (IGF-1) or factor-2 (IGF-2) wherein at least the glutamic acid residue is absent at position 3 from the N-terminal of IGF-1 or at position 5 or 6 from the N-terminal of IGF-2.
2. A peptide analogue according to claim 1 which is a human, bovine, ovine, porcine or chicken insulin-like growth factor analogue.
3. A peptide analogue according to claim 2 which is a human, bovine or porcine insulin-like growth factor-1 analogue.
4. A peptide analogue according to claim 3 wherein in addition at least one of the Gly-, Pro-, or Thr- residues is absent from the N-terminal.
5. A peptide analogue according to claim 3 wherein the glutamic acid residue is replaced by a different amino acid residue.
6. A peptide analogue according to claim 5 wherein the amino acid residue is replaced by a positively charged amino acid residue.
7. A peptide analogue according to claim 6 wherein the threonine residue normally adjacent the glutamic acid residue is replaced by a different amino acid residue.
8. A peptide analogue according to claim 1 having an N-terminal sequence selected from
Val-Leu-Cys-
Arg-Leu-Cys-
Gly-Leu-Cys-
Gly-Thr-Leu-Cys-
Gly-Pro-Arg-Thr-Leu-Cys- Gly-Pro-Gly-Arg-Leu-Cys-
Gly-Pro-Gly-Gly-Leu-Cys-
Gly-Pro-Gly-Thr-Leu-Cys-
Gly-Pro-Gln-Thr-Leu-Cys-
Gly-Pro-Lys-Thr-Leu-Cys-
Gly-Pro-Leu-Thr-Leu-Cys- with the Cys residue shown being that normally at position 6 from the N-terminal.
9. A peptide analogue according to claim 1 which is suitable for cleavage of an engineered upstream asparagine residue, including a terminal glycine residue.
10. A peptide analogue according to claim 1 in a biologically pure form.
11. A peptide analogue according to claim 1 which is a human, bovine, ovine, porcine or chicken insulin-like growth factor-2 analogue (IGF-2).
12. A peptide analogue according to claim 11 wherein in addition at least one of the Ala-, Tyr-, Arg-, Pro-, Ser- or Thr- residues is absent from the N-terminal.
13. A peptide analogue according to claim 11 wherein the glutamic residue is replaced by a different amino acid residue.
14. A peptide analogue according to claim 13 wherein the amino acid residue is replaced by a positively charged amino acid residue.
15. A peptide analogue according to claim 14 wherein the threonine residue normally adjacent the glutamic acid residue is replaced by a different amino acid residue.
16. A peptide analogue according to claim 13 having an - 21 -
N-terminal sequence selected from
Ala-Thr-Arg-Pro-Ser-Lys-Thr-Leu-Cys-
Ala-Tyr-Arg-Pro-Ser-Arg-Thr-Leu-Cys-
Ala-Tyr-Arg-Pro-Ser-Gly-Arg-Leu-Cys-
Ala-Tyr-Arg-Pro-Ser-Gly-Thr-Leu-Cys- with the Cys residue shown being that normally at position 9 from the N-terminal.
17. A peptide analogue according to claim 11 suitable for cleavage of an engineered upstream asparagine residue, including a terminal glycine residue.
18. A pharmaceutical or veterinary composition for the treatment of protein accumulation deficiencies or protein loss in animals including
(a) an effective amount of a peptide analogue of insulin¬ like growth factor-1 (IGF-1) or factor-2 (IGF-2) wherein at least the glutamic acid residue is absent at position 3 from the N-terminal of IGF-1 or at position 5 or 6 from the N-terminal of IGF-2 and
(b) a pharmaceutically or veterinarily acceptable diluent carrier or excipient therefor.
19. A pharmaceutical or veterinary composition according to claim 18 wherein the glutamic acid residue in the peptide analogue is substituted by a different amino acid residue.
20. A pharmaceutical or veterinary compositoin according to claim 19 wherein the peptide analogue is present in amounts of from approximately 0.02 to 2000 milligrams.
21. A method for the treatment of protein accumulation deficiencies or protein loss in human subjects, which method includes administering to a patient to be treated an effective amount of a peptide analogue of insulin-like growth factor-1 (IGF-1) or factor-2 (IGF-2) wherein at least the glutamic acid residue is absent at position 3 from the N-terminal of IGF-1 or at position 5 or 6 from the N-terminal of IGF-2.
22. A method according to claim 21 wherein the glutamic acid residue in the peptide analogue is substituted by a different amino acid.
23. A method according to claim 22 wherein the protein accumulation defiencies are associated with infant prematurity, growth hormone deficiency, burns, infection, other trauma, cancer, cystic fibrosis, Duchenne muscular dystrophy, Becker dystrophy, autosomal recessive dystrophy, polymyositis, as well as other myopathies.
24. A method according to claim 23 wherein the peptide analogue is administered at a dose rate of approximately 0.01 to 10 milligrams per kilogram body weight per day.
25. A method for the treatment of wounds in animals including humans, which method includes administering to a patient to be treated an effective amount of a peptide analogue of mammalian insulin-like growth factor-1 (IGF-1) or factor-2 (IGF-2) wherein at least the glutamic acid residue is absent at position 3 from the N-terminal of IGF-1 or at position 5 or 6 from the N-terminal of IGF-2.
26. A method according to claim 25 wherein the glutamic acid residue in the peptide analogue is substituted by a different amino acid residue.
27. A method according to claim 26 wherein the peptide analogue is administered by injection or is applied externally in amounts of approximately 0.02 to 2000 milligrams.
28. A method for the improvement of growth performance in animals which method includes administering to an animal to be treated an effective amount of a peptide analogue of insulin-like growth factor-1 (IGF-1) or factor-2 (IGF-2) wherein at least the glutamic acid residue is absent at position 3 from the N-terminal of IGF-1 or at position 5 or 6 from the N-terminal of IGF-2.
29. A method according to claim 28 wherein improved growth performance is associated with increased growth rate, selective deposition of muscle, reduced amount of fat or increased food conversion efficiency.
30. A method according to claim 29 wherein the peptide analogue is administered at a dose rate of approximately 0.01 to 10 milligrams/kg body weight/day.
31. A method for improviing the growth of cells in culture which method includes providing a culture medium and an effective amount of a peptide analogue of insulin-like growth factor-1 (IGF-1) or factor-2 (IGF-2) wherein at least the glutamic acid residue is absent at position 3 from the N-terminal of IGF-1 or at position 5 or 6 from the N-terminal of IGF-2; and adding the peptide analogue to the culture medium.
32. A method according to claim 31 wherein the peptide analogue is added in an amount of approximately 0.1 to 100 milligrams per litre of culture medium.
33. A method for the preparation of a peptide analogue of insulin-like growth factor-1 (IGF-1) wherein at least the glutamic acid residue is absent at position 3 from the N-terminal which method includes providing a source of amino acids, and coupling the amino acids in sequence to form a peptide analogue having an N-terminal sequence selected from,
Val-Leu-Cys-
Arg-Leu-Cys-
Gly-Leu-Cys-
Gly-Thr-Leu-Cys-
Gly-Pro-Arg-Thr-Leu-Cys-
Gly-Pro-Gly-Arg-Leu-Cys-
Gly-Pro-Gly-Gly-Leu-Cys-
Gly-Pro-Gly-Thr-Leu-Cys-
Gly-Pro-Gln-Thr-Leu-Cys-
Gly-Pro-Lys-Thr-Leu-Cys-
Gly-Pro-Leu-Thr-Leu-Cys- with the Cys residue being that normally at position 6 from the N-terminal.
34. A method according to claim 33 substantially as hereinbefore particularly described with reference to example 1.
0640V
PCT/AU1988/000485 1987-12-24 1988-12-20 Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2) WO1989005822A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP89900786A EP0346429B1 (en) 1987-12-24 1988-12-20 Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
DE3852636T DE3852636T2 (en) 1987-12-24 1988-12-20 PEPTIDE ANALOGS FROM INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) OR FACTOR 2 (IGF-2).

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPI6068 1987-12-24
AUPI606887 1987-12-24

Publications (1)

Publication Number Publication Date
WO1989005822A1 true WO1989005822A1 (en) 1989-06-29

Family

ID=3772677

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1988/000485 WO1989005822A1 (en) 1987-12-24 1988-12-20 Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)

Country Status (7)

Country Link
US (1) US5164370A (en)
EP (1) EP0346429B1 (en)
JP (1) JP2507106B2 (en)
AT (1) ATE116335T1 (en)
CA (1) CA1341204C (en)
DE (1) DE3852636T2 (en)
WO (1) WO1989005822A1 (en)

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0515434A1 (en) * 1990-02-13 1992-12-02 Gropep Pty. Ltd. Method for treating intestinal diseases
WO1993003152A1 (en) * 1991-07-29 1993-02-18 British Bio-Technology Limited Igf-ii analogues
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
WO1993023067A1 (en) * 1992-05-08 1993-11-25 Thomas Jefferson University Igf-1 analogs
WO1993025219A1 (en) * 1992-06-12 1993-12-23 Cephalon, Inc. Prevention and treatment of peripheral neuropathy
US5330971A (en) * 1989-06-09 1994-07-19 Gropep Pty. Ltd. Growth hormone fusion proteins, methods of production, and methods of treatment
WO1994026300A1 (en) * 1993-05-12 1994-11-24 Pharmacia Ab Insulin-like growth factor ii as antitumour agent
WO1995008567A1 (en) * 1993-09-20 1995-03-30 Celtrix Pharmaceuticals, Inc. Treatment of immunologic and hematologic disorders with igfbp alone or complexed with igf
US5420112A (en) * 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy
US5444045A (en) * 1992-09-17 1995-08-22 Gropep, Pty. Ltd. Method of administering IGF-1, IGF-2, and analogs thereof to birds
US5482926A (en) * 1992-06-08 1996-01-09 Pharmacia Ab Growth factor IGF-Il
US5597802A (en) * 1990-06-07 1997-01-28 Genentech, Inc. Method of formulating IGF-I with growth hormone
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5679771A (en) * 1990-02-13 1997-10-21 Gropep Pty. Ltd. Method for treating intestinal diseases
US5710127A (en) * 1992-06-08 1998-01-20 Pharmacia & Upjohn Aktiebolag Use of growth factor IGF-I and/or IGF-II
US5744139A (en) * 1991-06-28 1998-04-28 University Of Tennessee Research Corporation Insulin-like growth factor I (IGF-1) induced improvement of depressed T4/T8 ratios
WO2000005262A1 (en) * 1998-07-22 2000-02-03 The University Of Connecticut Uses of igf-i e domain peptides
US6034059A (en) * 1990-08-24 2000-03-07 Chiron Corporation Treatment of catabolic states using authentic IGF-1 and hypocaloric amount of nutrients
US6071880A (en) * 1996-09-16 2000-06-06 Dalhousie University Use of IGF-I for the treatment of renal insufficiencies, steriod toxicity and related indications
WO2000040612A1 (en) * 1999-01-06 2000-07-13 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
WO2000040613A1 (en) * 1999-01-06 2000-07-13 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6693076B1 (en) 1989-06-05 2004-02-17 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6723699B1 (en) 1989-06-05 2004-04-20 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
EP1506972A1 (en) * 1999-01-06 2005-02-16 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
US7041314B2 (en) 2001-05-24 2006-05-09 Neuren Pharmaceuticals Ltd. GPE analogs and peptidominetics
US7118752B2 (en) 1998-07-22 2006-10-10 University Of Connecticut Compositions and methods for inhibiting the proliferation and invasiveness of malignant cells comprising E-domain peptides of IGF-I
US7423017B2 (en) 1997-04-04 2008-09-09 Genentech, Inc. Method for treating cartilage disorders
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7700353B2 (en) 1998-07-22 2010-04-20 E-P Therapeutics, Inc. Compositions and methods for inducing apoptosis in tumor cells
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
EP2172480A3 (en) * 2005-02-21 2010-09-08 Chugai Seiyaku Kabushiki Kaisha Methods for producing proteins using hamster IGF-1
WO2010109053A1 (en) 2009-03-27 2010-09-30 Proyeto De Biomedicina Cima, S.L. Methods and compositions for the treatment of cirrhosis and liver fibrosis
EP2274978A1 (en) 2003-09-12 2011-01-19 Tercica, Inc. Methods for treatment of insulin-like growth factor-I(IGF-I) deficiency
US8343918B2 (en) 2006-06-09 2013-01-01 Novartis Ag Stabilized insulin-like growth factor polypeptides
US20150099699A1 (en) * 2004-12-22 2015-04-09 Hoffmann-La Roche Inc. Conjugates of insulin-like growth factor-1 and poly(ethylene glycol)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470828A (en) * 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
US5045531A (en) * 1989-12-18 1991-09-03 Magainin Sciences Inc. Wound treatment employing biologically active ion channel forming peptides and proteins
SE9002732D0 (en) * 1990-08-24 1990-08-24 Kabivitrum Ab PRODUCT CONTAINING GROWTH FACTOR
ES2174838T3 (en) * 1991-10-07 2002-11-16 Brigham & Womens Hospital METHOD TO INCREASE THE INTESTINE ABSORPTION.
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
ATE251466T1 (en) * 1999-04-08 2003-10-15 Genentech Inc COMPOSITION BASED ON OPPOSITELY CHARGED POLYPEPTIDES
BR0207422A (en) * 2001-02-09 2005-04-19 Genentech Inc Igf-1 crystal, composition, method of treating mammals suffering from agonist dysfunction, crystallization of igf-1, crystalline igf-1, identification methods of indirect igf-1 agonists, co-crystalline complex , igf-1 three-dimensional structure determination method, machine readable data storage medium, igf-1 crystal, igf-1 three-dimensional structure use method, igf-1 agonist or antagonist identification method, compound design method, peptidomimetic identification method, method for determining at least a three-dimensional structure part of a molecular complex, method for assessing the ability of a chemical entity to associate with igf-1, chemical entity, derivative of heavy atom, method of experimental or computational evaluation of a chemical entity and use of a composition
WO2002072780A2 (en) * 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
US20030124091A1 (en) * 2001-10-26 2003-07-03 Large Scale Biology Corporation Endothelial cell derived hematopoietic growth factor
JP2005534650A (en) * 2002-06-11 2005-11-17 ザ バーナム インスティテュート Neuroprotective synergism of erythropoietin and insulin-like growth factor
WO2005033134A2 (en) * 2003-09-30 2005-04-14 Regeneron Pharmaceuticals, Inc. Secreted protein therapeutics and uses thereof
JP2007537711A (en) * 2003-10-03 2007-12-27 ジェネンテック・インコーポレーテッド IGF binding protein
WO2006076342A2 (en) * 2005-01-11 2006-07-20 Heart Failure Technologies, Inc. Method and system for treating heart failure
HUE057135T2 (en) 2015-09-01 2022-04-28 Ncardia B V An in vitro method of differentiating a human pluripotent stem cell population into a cardiomyocyte cell population
WO2021005604A1 (en) 2019-07-11 2021-01-14 Opko Biologics Ltd. Long-acting igf-1 or igf-1 variants and methods of producing same
WO2024010729A1 (en) * 2022-07-05 2024-01-11 Terasaki Institute For Biomedical Innovation Dairy-based microstructures as microcarriers, scaffolds, substrates, and other applications

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6286986A (en) * 1985-08-22 1987-03-10 Gropep Pty Ltd Peptide analogues of mammalian insulin-like growth factor-1
AU6633086A (en) * 1985-12-13 1987-06-18 A.B. Kabigen Human fetal somatomedin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US408518A (en) * 1889-08-06 Stilt
US4196167A (en) * 1978-12-26 1980-04-01 California Medical Developments, Inc. Drug detection device
WO1985000831A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
US4745179A (en) * 1984-04-02 1988-05-17 Fujisawa Pharmaceutical Co., Ltd. 59 Valine insulin-like growth factor I and process for production thereof
SE8403479L (en) * 1984-06-29 1986-01-29 Ssab Svenskt Stal Ab SET TO MAKE PROFILED BODIES
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
EP0379338A3 (en) * 1989-01-17 1991-07-24 Merck & Co. Inc. Human insulin-like growth factor analogs and their production in yeast

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6286986A (en) * 1985-08-22 1987-03-10 Gropep Pty Ltd Peptide analogues of mammalian insulin-like growth factor-1
AU6633086A (en) * 1985-12-13 1987-06-18 A.B. Kabigen Human fetal somatomedin

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol 109, No.3, issued 1988, July 18, (Columbus, Ohio, U.S.A.), BAYNE, MARVIN L., et all., 'Structural Analogs of Human Insulin-like Growth Factor I with Reduced Affinity for Serum Binding Proteins and the Type 2 Insulin-Like Growth Factor Receptor.', page 68, Abstract No. 17150r, J.Biol.Chem. 1988, 263(13), 6233-9 (Eng). *
CHEMICAL ABSTRACTS, Vol. 105, No. 5, issued 1986, August 4, (Columbus, Ohio, U.S.A.), CARLSSON-SKWIRUT, CHRISTINE, et al., 'Isolation and Characterisation of Variant IGF-1 as well as IGF-2 from Adult Human Brain', page 147, Abstract No. 3636w, FEBS Lett. 1986, 201(1), 46-50. *
CHEMICAL ABSTRACTS, Vol.104, No. 23, issue 1986, June 9, (Columbus Ohio, U.S.A.) BLUMBERG, SHMARYAHU, et al., 'Removing N-Terminal Amino Acid Residues from Eukaryotic Polypeptide Analogues and Polypeptides Produced by this Method', page 410,Abstracts No. 203501c, PCT Int. Appl. WO 86 01,229, 27 Feb 1986, US appl. 641,488, 16 Aug 1984. *
CHEMICAL ABSTRACTS, Vol.105, No. 9, issued 1986, September 1, (Columbus, Ohio, U.S.A.) SARA, VICKI R., et al., 'Characterisation of Somatomedins from Human Fetal Brain: Identification of a Variant Form of Insulin-like Growth Factor I', page 142, Abstract No. 73328j, Proc. Natl. Acad. Sci. U.S.A. 1986, 83(13), 4904-7 (Eng). *
CHEMICAL ABSTRACTS, Vol.106, No.13, issued 1987, March 30, (Columbus, Ohio, U.S.A.), CARLSSON-SKWIRUT, C., et al., 'Circulating Forms of Human Fetal Somatomedin', page 156, Abstract No. 96902b, Acta Endocrinol. (Copenhagen) 1987, 114(1), 37-40 (Eng). *
CHEMICAL ABSTRACTS, Vol.108, No.23, issued 1988, June 6, (Columbus, Ohio, U.S.A.) DAWE, S.R. et al., 'Purification, Partial Sequences and Properties of Chicken Insulin-like Growth Factors.', page 421, Abstract No. 202006r, J. Endocrinol. 1988 117(2), 173-81 (Eng). *
CHEMICAL ABSTRACTS, Vol.108, No.23, issued 1988, June 6, (Columbus, Ohio, U.S.A.), FRANCIS, GEOFFREY L., et al., 'Insulin-like Growth Factors 1 and 2 in Bovine Colostrum. Sequences and Biological Activities Compared with those of a Potent Truncated form.', page 82, Abstract No. 198502e, Biochem.J., 1988, 251(1), 95-103 (Eng). *
CHEMICAL ABSTRACTS, Vol.109, No.11, issued 1988, September 12, (Columbus, Ohio, U.S.A.), CASCIERI,MARGARET A., et al., 'Serum Half-Life and Biological Activity of Mutants of Insulin-like Growth Factor I which do not Bind To Serum Binding Proteins.', page 146, Abstract No. 86924h, Endocrinology, (Baltimore) 1988, 123(1), 373-81 (Eng). *

Cited By (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693076B1 (en) 1989-06-05 2004-02-17 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5703045A (en) * 1989-06-05 1997-12-30 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5776897A (en) * 1989-06-05 1998-07-07 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6723699B1 (en) 1989-06-05 2004-04-20 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5330971A (en) * 1989-06-09 1994-07-19 Gropep Pty. Ltd. Growth hormone fusion proteins, methods of production, and methods of treatment
EP0515434A4 (en) * 1990-02-13 1993-06-16 Gropep Pty. Ltd. Method for treating intestinal diseases
EP0515434A1 (en) * 1990-02-13 1992-12-02 Gropep Pty. Ltd. Method for treating intestinal diseases
US5679771A (en) * 1990-02-13 1997-10-21 Gropep Pty. Ltd. Method for treating intestinal diseases
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5597802A (en) * 1990-06-07 1997-01-28 Genentech, Inc. Method of formulating IGF-I with growth hormone
US6034059A (en) * 1990-08-24 2000-03-07 Chiron Corporation Treatment of catabolic states using authentic IGF-1 and hypocaloric amount of nutrients
US5744139A (en) * 1991-06-28 1998-04-28 University Of Tennessee Research Corporation Insulin-like growth factor I (IGF-1) induced improvement of depressed T4/T8 ratios
US5583109A (en) * 1991-06-28 1996-12-10 Genentech, Inc. Method of stimulating immune response
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
US5736363A (en) * 1991-07-29 1998-04-07 British Bio-Technology Limited IGF-II analogues
WO1993003152A1 (en) * 1991-07-29 1993-02-18 British Bio-Technology Limited Igf-ii analogues
US5854025A (en) * 1991-07-29 1998-12-29 British Biotech Pharmaceutical Limited IGF-II analogues
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
US5473054A (en) * 1992-05-08 1995-12-05 Thomas Jefferson University IGF-1 analogs
WO1993023067A1 (en) * 1992-05-08 1993-11-25 Thomas Jefferson University Igf-1 analogs
US5482926A (en) * 1992-06-08 1996-01-09 Pharmacia Ab Growth factor IGF-Il
US5710127A (en) * 1992-06-08 1998-01-20 Pharmacia & Upjohn Aktiebolag Use of growth factor IGF-I and/or IGF-II
US5569648A (en) * 1992-06-12 1996-10-29 Cephalon, Inc. Prevention and treatment of peripheral neuropathy
US5420112A (en) * 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy
WO1993025219A1 (en) * 1992-06-12 1993-12-23 Cephalon, Inc. Prevention and treatment of peripheral neuropathy
US5648335A (en) * 1992-06-12 1997-07-15 Cephalon, Inc. Prevention and treatment of peripheral neuropathy
US5633228A (en) * 1992-06-12 1997-05-27 Cephalon, Inc., Prevention and treatment of peripheral neuropathy
US5444045A (en) * 1992-09-17 1995-08-22 Gropep, Pty. Ltd. Method of administering IGF-1, IGF-2, and analogs thereof to birds
US5902788A (en) * 1993-05-12 1999-05-11 Pharmacia & Upjohn Aktiebolag Insulin-like growth factor II as antitumour agent
WO1994026300A1 (en) * 1993-05-12 1994-11-24 Pharmacia Ab Insulin-like growth factor ii as antitumour agent
WO1995008567A1 (en) * 1993-09-20 1995-03-30 Celtrix Pharmaceuticals, Inc. Treatment of immunologic and hematologic disorders with igfbp alone or complexed with igf
US5527776A (en) * 1993-09-20 1996-06-18 Celtrix Pharmaceuticals Treatment of immunologic and hematologic disorders with IGFBP alone or complexed with IGF
US6071880A (en) * 1996-09-16 2000-06-06 Dalhousie University Use of IGF-I for the treatment of renal insufficiencies, steriod toxicity and related indications
US6716586B1 (en) 1997-04-04 2004-04-06 Genentech, Inc. Insulin-like growth factor agonist molecules
US6683053B1 (en) 1997-04-04 2004-01-27 Genentech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6743894B1 (en) 1997-04-04 2004-06-01 Genentech, Inc. Insulin-like growth factor agonist molecules
US8110548B2 (en) 1997-04-04 2012-02-07 Genentech, Inc. Method for treating cartilage disorders
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US7947650B2 (en) 1997-04-04 2011-05-24 Genentech, Inc. Article of manufacture
US6251865B1 (en) 1997-04-04 2001-06-26 Genentech, Inc. Insulin-like growth factor agonist molecules
US7423017B2 (en) 1997-04-04 2008-09-09 Genentech, Inc. Method for treating cartilage disorders
US6713451B1 (en) 1997-04-04 2004-03-30 Genentech, Inc. Insulin-like growth factor agonist molecules
US6608028B1 (en) 1997-04-04 2003-08-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6608031B1 (en) 1997-04-04 2003-08-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6693079B1 (en) 1997-04-04 2004-02-17 Genentech, Inc. Insulin-like growth factor agonist molecules
US6620789B1 (en) 1997-04-04 2003-09-16 Genentech, Inc. Insulin-like growth factor agonist molecules
US6632794B1 (en) 1997-04-04 2003-10-14 Genentech, Inc. Insulin-like growth factor agonist molecules
US6635619B1 (en) 1997-04-04 2003-10-21 Genentech, Inc. Insulin-like growth factor agonist molecules
US6645775B1 (en) 1997-04-04 2003-11-11 Genentech, Inc. Insulin-like growth factor agonist molecules
US6677305B1 (en) 1997-04-04 2004-01-13 Genentech, Inc. Insulin-like growth factor agonist molecules
US6680298B1 (en) 1997-04-04 2004-01-20 Genentech, Inc. Insulin-like growth factor agonist molecules
US6750321B1 (en) 1997-04-04 2004-06-15 Genentech, Inc. Insulin-like growth factor agonist molecules
US6689751B1 (en) 1997-04-04 2004-02-10 Genentech, Inc. Insulin-like growth factor agonist molecules
US6949349B1 (en) 1997-04-04 2005-09-27 Genentech, Inc. Insulin-like growth factor agonist molecules
US6693078B1 (en) 1997-04-04 2004-02-17 Genentech, Inc. Insulin-like growth factor agonist molecules
US6610302B1 (en) 1998-07-22 2003-08-26 University Of Connecticut Anti-tumor activity of Ea-2 and Ea-4-peptide of pro-IGF-I
US7118752B2 (en) 1998-07-22 2006-10-10 University Of Connecticut Compositions and methods for inhibiting the proliferation and invasiveness of malignant cells comprising E-domain peptides of IGF-I
US7700353B2 (en) 1998-07-22 2010-04-20 E-P Therapeutics, Inc. Compositions and methods for inducing apoptosis in tumor cells
WO2000005262A1 (en) * 1998-07-22 2000-02-03 The University Of Connecticut Uses of igf-i e domain peptides
US6358916B1 (en) 1998-07-22 2002-03-19 Thomas T. Chen Biological activity of IGF-I E domain peptide
WO2000040612A1 (en) * 1999-01-06 2000-07-13 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
US6403764B1 (en) 1999-01-06 2002-06-11 Genentech, Inc. Insulin-like growth factor-1 protein variants
WO2000040613A1 (en) * 1999-01-06 2000-07-13 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
EP1506972A1 (en) * 1999-01-06 2005-02-16 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
US7105167B2 (en) 1999-01-06 2006-09-12 Genentech, Inc. Methods for treating clinical manifestations of GH/GF axis dysregulation by administration of an IGF-I variant
AU762351B2 (en) * 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
AU762047B2 (en) * 1999-01-06 2003-06-19 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
US8097587B2 (en) 1999-01-06 2012-01-17 Genentech, Inc. IGF-I protein variants for treating IGFBP-1-related disorders
US6509443B1 (en) 1999-01-06 2003-01-21 Genentech, Inc. IGF-I point variants
US6506874B1 (en) 1999-01-06 2003-01-14 Genentech, Inc. IGF-I variants
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7041314B2 (en) 2001-05-24 2006-05-09 Neuren Pharmaceuticals Ltd. GPE analogs and peptidominetics
EP2274978A1 (en) 2003-09-12 2011-01-19 Tercica, Inc. Methods for treatment of insulin-like growth factor-I(IGF-I) deficiency
US20150099699A1 (en) * 2004-12-22 2015-04-09 Hoffmann-La Roche Inc. Conjugates of insulin-like growth factor-1 and poly(ethylene glycol)
US9724425B2 (en) * 2004-12-22 2017-08-08 Hoffmann-La Roche Inc. Conjugates of insulin-like growth factor-1 and poly(ethylene glycol)
EP2172480A3 (en) * 2005-02-21 2010-09-08 Chugai Seiyaku Kabushiki Kaisha Methods for producing proteins using hamster IGF-1
US8062863B2 (en) 2005-02-21 2011-11-22 Chugai Seiyaku Kabushiki Kaisha Nucleic acids encoding hamster 1GF-1 proteins and methods thereof
US8343918B2 (en) 2006-06-09 2013-01-01 Novartis Ag Stabilized insulin-like growth factor polypeptides
US8722621B2 (en) 2006-06-09 2014-05-13 Novartis Ag Stabilized insulin-like growth factor polypeptides
WO2010109053A1 (en) 2009-03-27 2010-09-30 Proyeto De Biomedicina Cima, S.L. Methods and compositions for the treatment of cirrhosis and liver fibrosis

Also Published As

Publication number Publication date
CA1341204C (en) 2001-03-13
AU2900989A (en) 1989-07-19
EP0346429B1 (en) 1994-12-28
JP2507106B2 (en) 1996-06-12
AU612776B2 (en) 1991-07-18
DE3852636T2 (en) 1995-05-04
JPH02504279A (en) 1990-12-06
EP0346429A4 (en) 1990-10-10
DE3852636D1 (en) 1995-02-09
EP0346429A1 (en) 1989-12-20
ATE116335T1 (en) 1995-01-15
US5164370A (en) 1992-11-17

Similar Documents

Publication Publication Date Title
US5164370A (en) Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
US5470828A (en) Peptide analogs of insulin-like growth factor II
EP0235205B1 (en) Peptide analogues of mammalian insulin-like growth factor-1
EP0309050B1 (en) Human insulin-like growth factor analogs with reduced binding to serum carrier proteins and their production in yeast
US5861379A (en) Chimeric fatty body-pro-GRF analogs with increased biological potency
EP0429586B1 (en) Growth hormone fusion proteins
JPH0829097B2 (en) Fibroblast growth factor
JPH0674279B2 (en) Growth hormone releasing factor analog and method for producing the same
US5622932A (en) IGF-1 superagonists
US5783558A (en) Parathormone fragments, their preparation and medicaments containing these
US5023322A (en) Analogs of growth hormone releasing factor (GRF) and a method for the preparation thereof
IE840537L (en) Polypeptides containing growth hormone releasing factor
JPH0367589A (en) Low bonding human insulin-like growth contributing analogs against igf combined protein and their production in yeast
JP2677795B2 (en) Method for purification and isolation of somatomedin C consisting of two ionic forms
AU612776C (en) Peptide analogues of insulin-like growth factor 1 (IGF-1) or factor 2 (IGF-2)
US4732972A (en) Polypeptides having growth hormone releasing activity
CS121192A3 (en) Super-active analog of a growth-hormone releasing factor, process forpreparing thereof and a pharmaceutical composition which contains said analog
WO1988007091A1 (en) Porcine growth hormone analogs
RU2119800C1 (en) Growth hormone factor peptide analog and method and composition for stimulating growth hormone secretion
WO1987007617A1 (en) A novel protein, neuroleukin
DE3687042T2 (en) PEPTIDE ANALOGUE OF THE INSULINE-LIKE GROWTH FACTOR-1 IN MAMMALS.
Li Synthetic Somatomedin C/Insulinlike Growth Factor I
JPH0322987A (en) Novel dna and use thereof
HU205953B (en) Process for producing new analogues of growth hormon secretion stimulating hormon and pharmaceutical and veterinaryc compositions containing them as active components

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989900786

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989900786

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1989900786

Country of ref document: EP